This article is more than 5 years old. Information may no longer be current.
Targeted therapy improved OS in metastatic RCC
Click Here to Manage Email Alerts
Implementation of targeted therapy was associated with significant improvements in treatment rates and OS among patients with metastatic renal cell carcinoma, according to results of a retrospective study conducted in Denmark.
Researchers evaluated the use of targeted therapy in 744 Danish patients with metastatic renal cell carcinoma (mRCC) who were referred for first-line therapy with either immunotherapy, tyrosine kinase inhibitors or mTOR-inhibitors between 2006 and 2010.
The number of treated patients increased significantly between 2006 and 2010 (64% vs. 75%; P=.0188). Researchers also observed significant increases in first-line targeted therapy (22% vs. 75%; P<.0001), second-line therapy (20% vs. 40%; P=.0104) and median OS (11.5 months vs. 17.2 months; P=.0435) during the study period. Researchers reported no changes in survival among untreated patients.
Multivariate analysis validated known prognostic factors.
Treatment initiation in 2008 (HR=0.74; 95% CI, 0.55–0.99), 2009 (HR=0.72; 95% CI, 0.54–0.96) and 2010 (HR=0.63; 95% CI, 0.47–0.86) was significantly associated with longer OS compared with treatment initiation in 2006.
Longer OS also was associated with more than two treatment lines in patients with performance status of 0 or 1 (HR=0.76; 95% CI, 0.58-0.99) and performance status of 2 to 3 (HR=0.19; 95% CI, 0.06-0.60).
Disclosure: See the study for full list of disclosures.
Collapse
Click Here to Manage Email Alerts